Alnylam Pharmaceuticalsvs.Moderna
ALNY vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.5× larger than Moderna by market cap; year to date, Moderna leads (+131.5% vs −24.9%).
Side by side
| ALNY | MRNA | |
|---|---|---|
| Market cap | $39.9B | $27.2B |
| Price | $298.76 | $68.27 |
| Today | −4.5% | −10.8% |
| Return YTD | −24.9% | +131.5% |
| Return 1Y | −7.4% | +99.2% |
| P/E | 69.1 | — |
| P/S | 9.3 | 12.2 |
| P/B | 37.1 | 3.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →ModernaMRNA
American biotech company based on mRNA technology — known for the covid vaccine, with a pipeline in vaccines and oncology.
Full MRNA profile →More comparisons in Biotech & innovation
See where ALNY and MRNA sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →